The presence of drug-neutralizing antibodies (ADAs) and disease-causing autoantibodies can significantly reduce the efficacy of biotherapeutic treatments, limiting their potential in treating rare diseases and other conditions. Current methods for addressing these unwanted antibodies are often inefficient and can have broad effects on the immune system.

Ablevia is developing a platform of customizable, peptide-based biotherapeutics called Selective Antibody Depletion Compounds (SADCs) designed to selectively remove harmful antibodies from circulation while sparing the rest of the immune system. These injectable peptide decoys are engineered to target and sequester specific unwanted antibodies, including ADAs that neutralize biologics and autoantibodies that trigger autoimmune conditions. Ablevia's technology aims to improve the effectiveness of biologic drugs, viral vectors, and replacement therapies by eliminating interfering antibodies. The SADC platform can be adapted to address a range of diseases and conditions with unmet clinical needs where unwanted antibodies pose a challenge.

Customizable peptide-based compounds for selective antibody removal

Targets drug-neutralizing antibodies (ADAs) and disease-causing autoantibodies

Designed to spare the rest of the immune system

Applicable to biologics, viral vectors, and replacement therapies

Addresses antibody-related challenges in autoimmune conditions and neuroimmunological diseases

Aims to improve drug efficacy by eliminating interfering antibodies

Platform technology enabling rapid removal of unwanted antibodies

Ablevia's primary customers are preclinical and clinical developers of biotherapeutic treatments, particularly those focused on rare diseases and conditions with unmet clinical needs where ADAs or autoantibodies limit treatment efficacy.